 PALO ALTO, Calif., Oct. 1, 2021 PRNewswire -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced updated results from its ongoing Phase 2b proof-of-concept, open-label study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 ADH1. 